NL-OMON24775尚未招募不适用
First attempt success ratio of intravenous cannulation with the Veinplicity®
Catharina HospitalDepartment of anesthesiology, intensive care and pain medicineMichelangelolaan 25623 EJ Eindhoven0 个研究点目标入组 125 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 125
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •In order to be eligible to participate in this study, a patient must meet all of the following criteria:
- •Patients must be in the age of 18 years or older;
排除标准
- •A potential patient who meets any of the following criteria will be excluded from participation in this study:
- •Patients in which an intravenous catheter is already inserted on the ward;
研究者
相似试验
已完成
不适用
First attempt success ratio of intravenous cannulation with the Veinplicity®intraveneuze toegang, perifeerDifficult intravenous access / (peripheral) intravenous cannulation10062915NL-OMON44449Catharina-ziekenhuis125
尚未招募
不适用
comparison of ultrasound guided needle insertion success vs landmark guided in percutaneous tracheostomyCTRI/2021/02/031580Sangeeta Chakraborty
招募中
1 期
A Phase-I clinical study of intravenous AntiPlatelet, AntiCoagulant (APAC) in healthy subjects.CTRI/2023/04/051500Cadila Pharmaceutical Limited
进行中（未招募）
1 期
Trial to test the safety, half-life, and antiviral efficacy of a new drug (human antibody) called DZIF-10c (administered intravenously) in healthy volunteers and SARS-CoV-2-infected participantsSARS-CoV-2 infection (only mild to moderate disease)MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862EUCTR2020-003503-34-DEniversity of Cologne69
已完成
1 期
A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy VolunteersObesityNCT00509132Genaera Corporation42